Skip to contentpdufa.bio

mRNA-3927 Registrational

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

mRNA-3927 Registrational is a Moderna Inc. program in propionic acidemia. Its next catalyst is a Readout in Q4 2026.

MRNA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Propionic acidemia. Sponsor: Moderna Inc. (MRNA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026MRNA

Questions

When is mRNA-3927 Registrational's next FDA decision or readout?

The next tracked catalyst for mRNA-3927 Registrational is a Readout in Q4 2026.

What happened at mRNA-3927 Registrational's most recent FDA decision?

No FDA decision for mRNA-3927 Registrational is in our archive yet.

What is mRNA-3927 Registrational used for?

In our records mRNA-3927 Registrational is under review or in development for Propionic acidemia.

Who makes mRNA-3927 Registrational?

Moderna Inc. (MRNA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.